The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

PATIENTS WITH DACTYLITIS ACHIEVED RESOLUTION AS MEASURED BY DACTYLITIS COUNT1*

Sustained resolution of preexisting dactylitis up to 5 years1,a

Line graph showing sustained resolution of preexisting dactylitis up to 5 years. Please see full Important Safety Information.

aPALACE 1-3 pooled analysis. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24.

Patients treated with OTEZLA 30 mg BID achieved significantly greater improvement vs placebo in dactylitis count (mean change of -1.8 vs -1.3, P<0.01) at week 242†

*Pooled patient data from PALACE 1-3; includes all randomized patients with dactylitis (baseline dactylitis count >0; n = 633). Resolution was defined as a dactylitis count of 0.

LOCF; for patients who qualified for early escape at week 16, the week 16 value was carried forward.

BID, twice daily; LOCF, last observation carried forward; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.

PATIENTS WITH DACTYLITIS ACHIEVED RESOLUTION IN A REAL-WORLD SETTING2*

Resolution of preexisting dactylitis at months 1 and 42,a

PSA-DST-DACT-REAL-WORLD

aLAPIS-PsA study, interim analysis at 4 months. Data as observed among patients with value available at specified time point.

In a real-world clinical setting, OTEZLA led to complete resolution of dactylitis2†

*Among patients with dactylitis count >0 at baseline (n = 32/110, 29.9%).

Defined as dactylitis count = 0.

LAPIS-PsA, Study of Apremilast Use in Patients with Psoriatic Arthritic in Practice Conditions.

References:

  1. Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019;21(1):118.
  2. Gladman DD, Kavanaugh A, Gómez-Reino JJ, et al. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018;4(1):e000669.
  3. Wollenhaupt J, Vollmer M, Berger S, Bach C, Altmann M, Nunez Gomez N. Real-world insights on apremilast treatment in psoriatic arthritis patients: interim analysis of the multicenter LAPIS-PsA study. Presented at: the 45th Congress of the German Society of Rheumatology (DGRh); 6-9 September 2017; Stuttgart, Germany.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.